Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Shares of Viking Therapeutics VKTX lost 18% yesterday after pharma ... another company developing a potential obesity drug, also plummeted 11% post Merck’s announcement. Year to date, Viking ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

VKTX’s Non-Obesity Pipeline Shows Potential Apart from VK2735, Viking is also developing drugs targeting non-alcoholic steatohepatitis (NASH) and X-linked adrenoleukodystrophy (X-ALD ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.

VKTX’s shares are currently trading below the 50 and 200-day moving averages. Though this biotech’s progress with its obesity drug has been encouraging, the rising competition for developing ...